Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Cancer Drugs Fund

This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

That's great news for BMS, which has fallen far behind its main rival, MSD's Keytruda in the biggest cancer market, non-small cell lung cancer. ... However, this availability will only be available via the Cancer Drugs Fund (CDF), as NICE says the

Latest news

  • NICE lung cancer backing for Keytruda is biggest expansion yet NICE lung cancer backing for Keytruda is biggest expansion yet

    NICE has, however, only given the green light to MSD's drug via the Cancer Drugs Fund (CDF), as there isn’t enough evidence yet for routine NHS use. ... This also shows the value of the Cancer Drugs Fund, which gives NICE the option to approve

  • Gilead strikes deal with NHS England on CAR-T Yescarta Gilead strikes deal with NHS England on CAR-T Yescarta

    Yescarta has a UK list price of nearly £300, 000 per patient, but the company’s commercial agreement with NHS England has now led to NICE approval via the Cancer Drugs ... the chimeric antigen receptor (CAR), and then reinfused back into the patient

  • Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

    trace of the cancer left – offering hope of a long term remission or even a cure. ... Gilead’s managing director for the UK and Ireland Hilary Hutton-Squire told PME that she is confident of agreeing a deal, with access via the Cancer Drugs Fund (CDF)

  • Gilead optimistic about Yescarta deal in UK Gilead optimistic about Yescarta deal in UK

    Gilead has been in talks with NICE, its ‘managed access’ Cancer Drugs Fund (CDF) committee and specialised medicines budget holder NHS England for many months in the run-up to the ... Meanwhile, the immature data makes using the Cancer Drugs Fund the

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    It also says it cannot recommend the drug for use within the Cancer Drugs Fund (CDF) “because…it is not possible to assess whether nivolumab has plausible potential to be cost ... effective.” For the last couple of years NICE has called the shots

More from news
Approximately 48 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... Current projects include developing antibodies for use as

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run rate’

  • Opening up market access Opening up market access

    In this PME market access supplement we look at the direction of travel in France and Germany and there’s an introduction to the UK’s new-look Cancer Drugs Fund.

  • Stepping up to payer-driven market access Stepping up to payer-driven market access

    products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.

  • The price is right? The price is right?

    Health stakeholders should focus not on the cost of drugs but on the value they provide. ... Proposed changes to the Cancer Drugs Fund in England include provision for access at a provisional price that is considered potentially cost-effective.

More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest appointments

  • New health ministers and re-appointments after reshuffle New health ministers and re-appointments after reshuffle

    Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the

  • Celgene names general manager for UK and Ireland Celgene names general manager for UK and Ireland

    This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Quick links

Infographics

Multimedia